Most Recent
Cipla sues to invalidate Bristol-Myers’ patents for DVT drug
Intellectual Property 2023-09-20 11:03 pm By Cat Fredenburgh

Indian generic drug maker Cipla has sued pharmaceutical giants Bristol-Myers Squibb and Pfizer alleging the patents behind their blockbuster deep vein thrombosis drug Eliquis are […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Celgene drops patent suit against Dr Reddy’s over Revlimid generic
Intellectual Property 2022-02-25 11:15 am By Cat Fredenburgh

Bristol-Myers Squibb unit Celgene has dropped a lawsuit accusing Indian generics company Dr Reddy’s Laboraties of threatening to infringe its patent for Revlimid with the […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Dr Reddy’s must warn Celgene of plans to sell generic blockbuster cancer drug
Intellectual Property 2021-12-07 2:55 pm By Cindy Cameronne

Indian generics giant Dr Reddy’s Laboratories must give Bristol-Myers Squib unit Celgene Corporation three months’ notice before deciding to sell generic versions of blockbuster cancer […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Bristol-Myers Squibb denies claims in Merck Sharp & Dohme’s misuse of market power case
Competition & Consumer Protection 2021-08-06 3:06 pm By Miklos Bolza

Pharmaceutical giant Bristol-Myers Squibb will fight a case brought by Merck Sharp & Dohme alleging misuse of market power over stage IV melanoma treatments, telling […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Bristol-Myers Squibb accused of misusing market power with cancer treatment program
Competition & Consumer Protection 2021-07-19 2:55 pm By Miklos Bolza

Merck Sharp & Dohme has filed a lawsuit accusing rival drug company Bristol-Myers Squibb of misusing its market power by restricting access to a treatment […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Judge warns ‘enough’s enough’ in fight for damages over delayed Abilify generic
Intellectual Property 2021-06-03 10:52 am By Cat Fredenburgh

A judge has given Generic Health more time to file its evidence in a multimillion-dollar dispute with drug makers Otsuka and Bristol-Myers Squibbs over the […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Juno and Bristol-Myers Squibb suffer losses in Revlimid patent war
Intellectual Property 2021-03-25 1:58 pm By Miklos Bolza

A patent battle between Juno Pharmaceuticals and Bristol-Myers Squibb over the blockbuster drug Revlimid has seen both sides suffer early losses, with a judge dismissing […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Full Court hears government’s $325M fight with Sanofi over ban on Plavix generic
Intellectual Property 2021-02-16 4:13 pm By Miklos Bolza

Pharmaceutical companies Sanofi and Bristol-Myers Squibb are liable for losses to the federal government for excess subsidies it allegedly paid for the blood-thinner Plavix after […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Government loses case claiming $325M over generic Plavix delay
Intellectual Property 2020-04-28 6:05 pm By Miklos Bolza

A court has dismissed a claim by the Australian Government for $325 million against pharmaceutical companies Sanofi and Bristol-Myers Squibb allegedly owed for excess subsidies […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Otsuka ‘deliberately’ withheld information from court, Generic Health claims
Intellectual Property 2019-09-17 9:30 pm By Miklos Bolza

Pharmaceutical company Generic Health has told the Federal Court that, on advice from their solicitors, Otsuka and Bristol-Myers Squibb “deliberately” chose not to disclose their […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.